Related Experiment Videos
Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue
I B Joseph1, J B Nelson, S R Denmeade
1Johns Hopkins Oncology Center, Department of Urology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.
Abstract:
In previous studies, we have demonstrated that androgen ablation-induced growth inhibition of androgen-responsive PC-82 and A-2 human prostate cancer xenografts involves not only direct activation of programmed (apoptotic) death of these cells but also indirect activation of this death process via a decrease in tumor angiogenesis secondary to a reduction in tumor vascular endothelial growth factor (VEGF) levels. To determine whether androgens consistently regulate angiogenesis via control of VEGF levels, an additional human (i.e., LnCaP) and two rodent (i.e., Dunning G and H) androgen-sensitive prostate cancer sublines were tested. Androgen ablation causes a decrease in the subsequent growth rate of each of these three additional prostate cancer sublines, and this growth inhibition is consistently associated with a >60% reduction in tumor VEGF levels. To examine whether androgens regulate VEGF levels not only in malignant but also in normal prostatic tissue, male rats were castrated, and the temporal changes in the VEGF content of ventral prostate tissue were determined. One week after castration, VEGF content decreased to <20% within the ventral prostate. Subsequent replacement with exogenous androgen to long-term castrated rats stimulated an 8-fold rise in ventral prostate VEGF content within 1 week. To evaluate whether androgen regulation of VEGF is due to a direct effect of androgen on prostatic cells, the dose-response ability of androgens to increase VEGF levels in media of LnCaP cells grown in vitro was tested. These studies demonstrate that androgens directly stimulate VEGF secretion in these cells. The presence of 4-5-fold higher levels of VEGF in prostatic fluid versus seminal vesicle fluid obtained from benign prostatic hyperplasia and clinically localized prostate cancer patients suggests that elevated levels of VEGF may contribute to the progression of these prostatic conditions by promoting angiogenesis. In summary, one of the mechanisms for androgen sensitivity for the control of the growth of both normal and malignant prostatic tissue is via its stimulation of VEGF levels.
Insights
Androgens control prostate cancer growth by regulating vascular endothelial growth factor (VEGF). Androgen ablation reduces VEGF, inhibiting tumor growth and angiogenesis, while androgen replacement increases VEGF levels.
Area of Science:
- Oncology
- Endocrinology
- Molecular Biology
Background:
- Androgen ablation inhibits prostate cancer xenograft growth through apoptosis and reduced angiogenesis.
- Tumor angiogenesis is linked to vascular endothelial growth factor (VEGF) levels.
Purpose of the Study:
- To determine if androgens consistently regulate angiogenesis by controlling VEGF levels in various prostate cancer models.
- To investigate androgen regulation of VEGF in normal prostatic tissue.
- To assess if androgens directly stimulate VEGF secretion.
Main Methods:
- Tested androgen-sensitive human (LnCaP) and rodent (Dunning G and H) prostate cancer sublines.
- Performed castration and androgen replacement in male rats to measure ventral prostate VEGF.
- Assayed androgen-induced VEGF level changes in LnCaP cells in vitro.
Main Results:
- Androgen ablation decreased growth and reduced VEGF levels by >60% in tested sublines.
- Castration significantly decreased ventral prostate VEGF; androgen replacement increased it 8-fold.
- Androgens directly stimulated VEGF secretion in LnCaP cells.
- Elevated VEGF in prostatic fluid suggests a role in benign prostatic hyperplasia and prostate cancer progression.
Conclusions:
- Androgens directly stimulate VEGF production, influencing angiogenesis.
- Androgen sensitivity in prostate tissue growth involves VEGF regulation.
- Targeting the androgen-VEGF pathway may offer therapeutic strategies for prostate conditions.